9.09
price up icon6.07%   0.52
after-market Handel nachbörslich: 8.46 -0.63 -6.93%
loading
Schlusskurs vom Vortag:
$8.57
Offen:
$8.95
24-Stunden-Volumen:
331.76K
Relative Volume:
0.33
Marktkapitalisierung:
$458.03M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.7281
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
+6.94%
1M Leistung:
+15.65%
6M Leistung:
+14.34%
1J Leistung:
-32.67%
1-Tages-Spanne:
Value
$8.86
$9.10
1-Wochen-Bereich:
Value
$8.14
$9.10
52-Wochen-Spanne:
Value
$5.035
$15.36

Regenxbio Inc Stock (RGNX) Company Profile

Name
Firmenname
Regenxbio Inc
Name
Telefon
240-552-8181
Name
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Mitarbeiter
353
Name
Twitter
@REGENXBIO
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
RGNX's Discussions on Twitter

Vergleichen Sie RGNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RGNX
Regenxbio Inc
9.09 431.83M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Herabstufung Goldman Buy → Neutral
2025-02-07 Fortgesetzt Raymond James Outperform
2024-11-15 Fortgesetzt Morgan Stanley Overweight
2024-10-10 Fortgesetzt Raymond James Outperform
2024-06-07 Eingeleitet Goldman Buy
2024-03-11 Eingeleitet H.C. Wainwright Buy
2024-03-08 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-03-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-02-21 Fortgesetzt Raymond James Outperform
2023-11-01 Eingeleitet Stifel Buy
2023-06-02 Eingeleitet Robert W. Baird Outperform
2022-06-23 Eingeleitet Berenberg Buy
2021-12-15 Eingeleitet Wedbush Neutral
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-01-06 Hochstufung Raymond James Outperform → Strong Buy
2020-12-16 Eingeleitet UBS Buy
2020-06-25 Fortgesetzt BofA/Merrill Buy
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2019-08-20 Hochstufung SVB Leerink Underperform → Mkt Perform
2019-06-18 Bestätigt Chardan Capital Markets Buy
2019-06-14 Fortgesetzt Raymond James Outperform
2019-06-05 Bestätigt Chardan Capital Markets Buy
2019-02-25 Hochstufung Evercore ISI In-line → Outperform
2019-02-05 Hochstufung Raymond James Outperform → Strong Buy
2018-12-17 Bestätigt Chardan Capital Markets Buy
2018-11-08 Bestätigt BofA/Merrill Neutral
2018-08-08 Bestätigt Chardan Capital Markets Buy
2018-07-23 Herabstufung BofA/Merrill Buy → Neutral
2018-07-10 Bestätigt Chardan Capital Markets Buy
2018-05-09 Bestätigt Barclays Overweight
2018-04-09 Bestätigt Chardan Capital Markets Buy
2018-03-12 Herabstufung Evercore ISI Outperform → In-line
2018-02-13 Eingeleitet Mizuho Neutral
2017-11-09 Fortgesetzt Morgan Stanley Overweight
Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

pulisher
Jul 23, 2025

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives REGENXBIO Inc. stock priceOverwhelming profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about REGENXBIO Inc. stockFree Investment Risk Control - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

REGENXBIO Inc. Stock Analysis and ForecastMarket-beating performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 11, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Jul 11, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News

Jul 10, 2025
pulisher
Jul 09, 2025

Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com

Jul 09, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛

Jul 08, 2025
pulisher
Jun 16, 2025

Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 09, 2025

Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks

Jun 09, 2025
pulisher
Jun 07, 2025

REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Duchenne gene therapy interim trial outcomes "striking" - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive

Jun 06, 2025
pulisher
Jun 06, 2025

RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter

Jun 06, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech

Jun 05, 2025
pulisher
Jun 05, 2025

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg

Jun 05, 2025
pulisher
Jun 05, 2025

Transcript : REGENXBIO Inc.Special Call - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial - Investing.com Australia

Jun 05, 2025

Finanzdaten der Regenxbio Inc-Aktie (RGNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):